Antibodies
25 October 2011
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma Malignancies24 October 2011
Thallion Pharmaceuticals Inc.: Blinded Results From Low Dose Cohort of Phase II SHIGATEC Trial Presented at IDSA Annual Meeting24 October 2011
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study24 October 2011
Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasis21 October 2011
Xencor Initiates Phase 1 Study of XmAb5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases18 October 2011
Halozyme Announces Positive Results from Roche’s Subcutaneous Herceptin Phase 3 Trial17 October 2011
Update on Large Scale Manufacturing Outcomes for PAT-SM613 October 2011
Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALL11 October 2011
Study Shows That Roche’s Investigational Drug for Alzheimer’s Disease Removes Amyloid Plaques From the Brain30 September 2011
Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors29 September 2011
Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports